Use of ADCC-optimized antibodies for treating weak patients
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
1. A method for treating a cancer or an infection by a pathogenic agent, comprising:
administering a composition of antibodies to a patient in need thereof,
wherein said antibodies are specific to an antigen expressed by the cancer or infection to be treated in the patient,
wherein the cancer or infection has a number of antigenic sites below 250,000 per target cell, and
wherein said antibodies are over 60%, for the forms G0+G1+G0F+G1F, given that the forms G0F+G1F are lower than 50%, and
wherein said antibodies are selected from the group consisting of anti-HLA-DR, anti-CD20, anti Ep-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CA125, anti GD, anti GD2, anti CD-23 and anti Protein C, anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, and anti-CD44.
2. The method according to claim 1 , wherein said patient is homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or said patient is heterozygous for valine/phenylalanine in position 158 of CD16 (FCGR3A-158V/F).
3. The method according to claim 1 , wherein the number of antigenic sites is below 100,000 per target cell.
4. The method according to claim 3 , wherein the number of antigenic sites is below 50,000 per target cell.
5. The method according to claim 3 , wherein the number of antigenic sites is below 10,000 per target cell.
6. The method according to claim 1 , wherein the dose of said antibody administered to the patient is between 2 and 100 times lower than a dose of an antibody of the same specificity but of different glycosylation or produced in a CHO line.
7. The method according to claim 6 , wherein the dose of said antibody administered to the patient is between 5 and 25 times lower than a dose of an antibody of the same specificity but of different glycosylation or produced in a CHO line.
8. The method according to claim 1 , wherein the antibody is directed against an antigen of a cancer cell or of an organism pathogenic for humans.
9. The method according to claim 1 , wherein the antibody is anti-HLA-DR.
10. The method according to claim 1 , wherein the antibody is anti-CD20.